Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of AV-299 (Formerly SCH 900105) Administered by IV Infusion as Monotherapy in Advanced Solid Tumors, Lymphomas, or Multiple Myeloma or in Combination With Erlotinib in Advanced Solid Tumors

NCT00725634 is registered in ClinicalTrials.gov with AVEO Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00725634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00725634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of AV-299 (Formerly SCH 900105) Administered by IV Infusion as Monotherapy in Advanced Solid Tumors, Lymphomas, or Multiple Myeloma or in Combination With Erlotinib in Advanced Solid Tumors
Lead sponsor
AVEO Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2008
Completion date
December 31, 2013
Enrollment
41 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lymphomas, malignant solid tumor, multiple myeloma